TY - JOUR
T1 - Pregnancy in the Setting of Multiple Sclerosis
AU - Fabian, Michelle
N1 - Publisher Copyright:
© American Academy of Neurology.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Purpose of Review: This article provides a review of the available data on reproductive issues that arise in patients with multiple sclerosis (MS). Recent Findings: Recent findings have replicated earlier findings that pregnancy and possibly breast-feeding bring about a favorable immunomodulatory effect in patients with MS. Use of disease-modifying therapies prior to pregnancy may further decrease a patient's risk for postpartum disease activity. Summary: The annualized relapse rate in MS decreases during pregnancy, with a nadir in the third trimester, and rebounds significantly in the 3-month postpartum period. Exclusive breast-feeding may exert a beneficial effect in decreasing the postpartum risk for relapse. Certain assisted reproductive technology methods are thought to increase the risk for relapse. Disease-modifying therapies are generally discontinued during pregnancy and lactation with a few exceptions. The pregnancy course is usually routine without significant obstetric complications, and babies, although slightly smaller, are typically healthy.
AB - Purpose of Review: This article provides a review of the available data on reproductive issues that arise in patients with multiple sclerosis (MS). Recent Findings: Recent findings have replicated earlier findings that pregnancy and possibly breast-feeding bring about a favorable immunomodulatory effect in patients with MS. Use of disease-modifying therapies prior to pregnancy may further decrease a patient's risk for postpartum disease activity. Summary: The annualized relapse rate in MS decreases during pregnancy, with a nadir in the third trimester, and rebounds significantly in the 3-month postpartum period. Exclusive breast-feeding may exert a beneficial effect in decreasing the postpartum risk for relapse. Certain assisted reproductive technology methods are thought to increase the risk for relapse. Disease-modifying therapies are generally discontinued during pregnancy and lactation with a few exceptions. The pregnancy course is usually routine without significant obstetric complications, and babies, although slightly smaller, are typically healthy.
UR - http://www.scopus.com/inward/record.url?scp=84974652877&partnerID=8YFLogxK
U2 - 10.1212/CON.0000000000000328
DO - 10.1212/CON.0000000000000328
M3 - Review article
C2 - 27261685
AN - SCOPUS:84974652877
SN - 1080-2371
VL - 22
SP - 837
EP - 850
JO - CONTINUUM Lifelong Learning in Neurology
JF - CONTINUUM Lifelong Learning in Neurology
IS - 3
ER -